2024 Spain Hepatitis A, B, C, D, E Diagnostics Market: Supplier Shares and Strategies, Volume and Sales Segment Forecasts for Immunodiagnostic and NAT Tests, Technology and Instrumentation Review, Opportunities for Suppliers
The report presents a detailed analysis of the Hepatitis diagnostics market in Spain.The report is available by section, and can be customized to specific information needs and budget.Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides five-year test volume and sales forecasts for HAV NAT, HBV NAT, HBs Ag, HCV, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, and ALT/SGPT tests performed in the following markets:%li%Hospitals%li%Commercial/Private Labs%li%Blood BanksIn addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of Hepatitis tests.Also, the report examines the market applications of DNA Probes, Monoclonal Antibodies, Immunoassays, IT and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues and concerns.Contains 241 pages and 14 tables
I. Introduction
II. Major Product Development Opportunities
A. Instrumentation
B. Reagent Kits and Test Systems/Panels
C. Information Technology
D. Auxiliary Products
III. Design Criteria for Decentralized Testing Products
IV. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized
Testing Markets
V. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VI. Worldwide Overview of Major Tests,
Technologies, and Instrumentation
A. Major Infectious Disease Tests
1. AIDS: HIV/HIV-1/2/COMBO, HIVAG/HIV NAT,
Western Blot, HTLV-I/II
2. ADENOVIRUS
3. AEROMONAS
4. ANTHRAX/BACILLUS ANTHRACIS
5. ARBOVIRUSES
6. BABESIOSIS
7. BACILLARY EPITHELIOID ANGIOMATOSIS (BEA)
and Other Bartonella (Rochalimaea)
8. BLASTOCYSTIS HOMINIS
9. BRUCELLA
10. CAMPYLOBACTER
11. CANDIDA
Table of Contents (continued)
12. CHAGAS DISEASE
13. CHANCROID
14. CHLAMYDIA
15. CLOSTRIDIUM DIFFICILE
16. CORONAVIRUSES
17. COXSACKIEVIRUSES
18. CREUTZFELDT-JAKOB’S DISEASE
19. CRYPTOSPORIDIUM PARVUM
20. CYCLOSPORA CAYETANENSIS
21. CYTOMEGALOVIRUS
22. EBOLA VIRUS
23. E. COLI
24. ECHOVIRUS
25. ENCEPHALITIS
26. ENTEROVIRUSES
27. EPSTEIN-BARR VIRUS
28. GIARDIA LAMBLIA
29. GONORRHEA
30. GRANULOMA INGUINALE
31. HANTAVIRUS
32. HELICOBACTER PYLORI
33. HEPATITIS: HAV NAT, HBV NAT, HBS AG, HCV, HCV NAT,
Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag,
HBe Ag, ALT/SGPT
34. HERPES SIMPLEX VIRUS
35. HUMAN HERPES VIRUS-6 (HHV-6)
36. INFLUENZA VIRUSES
37. LEGIONELLA
38. LYME DISEASE
39. LYMPHOGRANULOMA VENEREUM (LGV)
40. MALARIA
41. MEASLES (RUBEOLA)
42. MENINGITIS
43. MICROSPORIDIUM
44. MONONUCLEOSIS
45. MUMPS
46. MYCOPLASMA
47. PAPILLOMAVIRUSES
48. PARVOVIRUS B19
49. PNEUMONIA
50. POLYOMAVIRUSES
51. PSEUDOMONAS AERUGINOSA
52. RABIES
53. RESPIRATORY SYNCYTIAL VIRUS (RSV)
54. RHINOVIRUSES
55. ROTAVIRUS
II. Major Product Development Opportunities
A. Instrumentation
B. Reagent Kits and Test Systems/Panels
C. Information Technology
D. Auxiliary Products
III. Design Criteria for Decentralized Testing Products
IV. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized
Testing Markets
V. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VI. Worldwide Overview of Major Tests,
Technologies, and Instrumentation
A. Major Infectious Disease Tests
1. AIDS: HIV/HIV-1/2/COMBO, HIVAG/HIV NAT,
Western Blot, HTLV-I/II
2. ADENOVIRUS
3. AEROMONAS
4. ANTHRAX/BACILLUS ANTHRACIS
5. ARBOVIRUSES
6. BABESIOSIS
7. BACILLARY EPITHELIOID ANGIOMATOSIS (BEA)
and Other Bartonella (Rochalimaea)
8. BLASTOCYSTIS HOMINIS
9. BRUCELLA
10. CAMPYLOBACTER
11. CANDIDA
Table of Contents (continued)
12. CHAGAS DISEASE
13. CHANCROID
14. CHLAMYDIA
15. CLOSTRIDIUM DIFFICILE
16. CORONAVIRUSES
17. COXSACKIEVIRUSES
18. CREUTZFELDT-JAKOB’S DISEASE
19. CRYPTOSPORIDIUM PARVUM
20. CYCLOSPORA CAYETANENSIS
21. CYTOMEGALOVIRUS
22. EBOLA VIRUS
23. E. COLI
24. ECHOVIRUS
25. ENCEPHALITIS
26. ENTEROVIRUSES
27. EPSTEIN-BARR VIRUS
28. GIARDIA LAMBLIA
29. GONORRHEA
30. GRANULOMA INGUINALE
31. HANTAVIRUS
32. HELICOBACTER PYLORI
33. HEPATITIS: HAV NAT, HBV NAT, HBS AG, HCV, HCV NAT,
Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag,
HBe Ag, ALT/SGPT
34. HERPES SIMPLEX VIRUS
35. HUMAN HERPES VIRUS-6 (HHV-6)
36. INFLUENZA VIRUSES
37. LEGIONELLA
38. LYME DISEASE
39. LYMPHOGRANULOMA VENEREUM (LGV)
40. MALARIA
41. MEASLES (RUBEOLA)
42. MENINGITIS
43. MICROSPORIDIUM
44. MONONUCLEOSIS
45. MUMPS
46. MYCOPLASMA
47. PAPILLOMAVIRUSES
48. PARVOVIRUS B19
49. PNEUMONIA
50. POLYOMAVIRUSES
51. PSEUDOMONAS AERUGINOSA
52. RABIES
53. RESPIRATORY SYNCYTIAL VIRUS (RSV)
54. RHINOVIRUSES
55. ROTAVIRUS
